FORMULATION AND EVALUATION OF TRAZODONE HYDROCHLORIDE ORODISPERSIBLE TABLETS

Akiladevi D

doi:10.22159/ajpcr.2018.v11s4.31740

Authors

Akiladevi D Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Chennai, Tamil Nadu, India.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11s4.31740

Keywords:

FlowLac, Orodispersible, StarLac, Trazodone hydrochloride

Abstract

Objective: The objective of the existing research was to develop an oral disintegrating dissolving system as one of the taste masking orodispersible forms together of trazodone hydrochloride tablets using direct compression technique through the use of superdisintegrants together with FlowLac, StarLac, and sodium starch glycolate.

Methods: The tablets were formulated using the direct compression approach. The drugs prepared have been evaluated for diverse parameters which include hardness, friability, weight variation, drug content uniformity, water absorption ratio, in vitro drug release, and wetting time.

Results: The hardness of all formulations from F1 to F7 proved that the tablet means thickness was nearly uniform in all formulations with the range of 0.520 mmâ€“0.522 mm. Water absorption of prepared formulations was found to be 68.59%â€“73.21%. Bulk density, tapped density, and friability of the formulations were established within the limits, results of in vitro drug release study showed the drug released between 90.27% and 96.17% at 60 min.

Conclusion: The overall study concluded that orodispersible tablets of trazodone hydrochloride have greater dissolution rate and will result in enhanced bioavailability. The taste masked systems are designed to provide better acceptability, improved bioavailability, for chronic patients. The study results revealed that the formulation F6 was contemplated as the top formulation.

Downloads

Download data is not yet available.

References

Behnke KSogaard JMartin SBauml JRavindran AVAgren HLachmann L, Liebermann AH. The Theory and Practice of Industrial Pharmacy. 3rd ed. New York: Lippincott Williams and Wilkins Publisher; 1986.

Allen VL, Popovich NG, Ansel CH. Anselâ€™s Pharmaceutical dosage form and drug delivery system 8th ed. New York: Lippincott Williams and Wilkins Publisher; 2005.

Bentley AO. Ernest Alexander Rawlins. Bentleyâ€™s Textbook of Pharmaceutics.8th ed. London: Bailliere Tindall Publisher; 1995.

Sastry SV, Nyashadam JR, Fix JA. Recent technological advances in oral drug delivery: A review. Pharm Sci Technolo Today 2000;3:138-45.

Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: Developments, technologies, taste-masking and clinical studies. Crit Rev Ther Drug Carrier Syst 2004;21:433-76.

Seager H. Drug-delivery products and the zydis fast-dissolving dosage form. J Pharm Pharmacol 1998;50:375-82.

Habib W, Khankari R, Hontz J. Fast-dissolve drug delivery systems. Crit Rev Ther Drug Carrier Syst 2000;17:61-72.

Dobetti L. Fast disintegrating tablets. US Patent 2003;6:596,311.

Brown D. Orally disintegrating tablets taste over speed. Drug Del Tech 2003;3:58-61.

Behnke K, Sogaard J, Martin S, Bauml J, Ravindran AV, Agren H, et al. Mirtazapine orally disintegrated tablet versus sertaline. A prospective onset of action study. J Clin Psychopharmacol 2003;23:358-64.

Jaccard TT, Leyder J. Une nouvelle forme galenique le lyoc. Ann Pharm Fr 1985;43:123-31.

Dollo G, Chevanne F, Le Corre P, Chemtob C, Le Verge R. Bioavailability of phloroglucinol in man. J Pharm Belg 1999;54:75-82.

GafiÅ£anu E, DumistrÄƒcel I, Antochi S. Formulations and bioavailability of propyphenazone in lyophilized tablets. Rev Med Chir Soc Med Nat Iasi 1991;95:127-8.

Clarke A, Brewer F. A new formulation of selegiline: Improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 2003;110:124-5.

Dobetti L. Fast melting tablets: Developments and technologies. Pharm Technol Drug Deliv 2001;25 Supp1 9:44-50.

Meyers GL, Battist GE, Fuisz RC. Process and Apparatus for Making Rapidly Dissolving Dosage units and Products there Form. PCT Patent WC No. 95/34293-A1; 1995.

Allen LV, Wang B. Process for making a particulate support matrix for making a rapidly dissolving dosage forms. US Patent 2001;6:199-207.

Kuno Y, Kojima M, Ando S, Nakagami H. Evaluation of rapidly disintegrating tablets manufactured by phase transition of sugar alcohols. J Control Release 2005;105:16-22.

Yu DG, Shen XX, Han J, Zhu LM, Branford-White C, Li XY, et al. Oral Fast-Dissolving DDD Fabricated Using 3DP, Bioinformatics and Biomedical Engineering. The 2nd International Conference; 2008. p. 1602-5.

Gregory GK. Pharmaceutical Dosage form Packages. US patent 1981;4:305-502.

Schatzberg AF, Nemeroff CB, editors. Textbook of Psychopharmacology. 4th ed. Washington, DC: American Psychiatric Publisher; 2009.